Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial-Reference-Cited by-同舟云学术

Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial

Published:2017-04 Issue:4 Volume:2 Page:277-287
ISSN:2468-1253
Container-title:The Lancet Gastroenterology & Hepatology
language:en
Short-container-title:The Lancet Gastroenterology & Hepatology

Author:

Shitara Kohei,Takashima Atsuo,Fujitani Kazumasa,Koeda Keisuke,Hara Hiroki,Nakayama Norisuke,Hironaka Shuichi,Nishikawa Kazuhiro,Makari Yoichi,Amagai Kenji,Ueda Shinya,Yoshida Kazuhiro,Shimodaira Hideki,Nishina Tomohiro,Tsuda Masahiro,Kurokawa Yukinori,Tamura Takao,Sasaki Yasutsuna,Morita Satoshi,Koizumi Wasaburo

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference24 articles.

1. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial;Bang;Lancet,2010

2. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO);Thuss-Patience;Eur J Cancer,2011

3. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone;Kang;J Clin Oncol,2012

4. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial;Ford;Lancet Oncol,2014

5. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial;Hironaka;J Clin Oncol,2013

Cited by 151 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in clinical application of nanoparticle-based therapy for cancer treatment: A systematic review;Nano TransMed;2024-12

2. A translational framework to DELIVER nanomedicines to the clinic;Nature Nanotechnology;2024-09-06

3. Hyaluronidase improves the efficacy of nab-paclitaxel after prolonged angiogenesis inhibition in preclinical models for esophagogastric cancer;Biomedicine & Pharmacotherapy;2024-09

4. A retrospective study of adjuvant albumin-bound paclitaxel plus S-1 after D2 gastrectomy versus oxaliplatin plus S-1 in gastric cancer;Scientific Reports;2024-07-02

5. A phase 1 study of biweekly nab-paclitaxel/oxaliplatin/S-1/LV for advanced upper gastrointestinal cancers: TCOG T1216 study;The Oncologist;2024-06-21